Trevena Inc

Trevena Inc is an American biopharmaceutical company that focuses on the development of pharmaceutical drugs for the treatment of various medical conditions. The company was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania.

History

Trevena Inc was established in 2007 by a team of experienced biotechnology professionals. The company's initial focus was on the development of G protein-coupled receptor (GPCR) targeted medicines. Over the years, Trevena has expanded its research and development efforts to include a wide range of therapeutic areas.

Products and Research

Trevena's product portfolio includes a number of innovative drugs that are designed to address unmet medical needs. The company's lead product, Oliceridine, is a novel opioid receptor agonist that has been approved by the Food and Drug Administration (FDA) for the management of moderate to severe acute pain.

In addition to Oliceridine, Trevena is also developing a number of other drugs in various stages of clinical development. These include TRV027, a Beta-arrestin biased angiotensin II receptor type 1 (AT1R) ligand for the treatment of acute heart failure, and TRV250, a delta receptor selective GPCR biased ligand for the treatment of acute migraine.

Financial Performance

As a publicly traded company, Trevena Inc's financial performance is closely watched by investors and analysts. The company's revenue primarily comes from the sales of its approved drugs and from partnerships with other pharmaceutical companies.

See Also

• Biopharmaceutical
• Pharmaceutical industry in the United States
• List of pharmaceutical companies

References

<references />

   This article is a biopharmaceutical company stub. You can help WikiMD by expanding it!

This biopharmaceutical company related article is a stub.